Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis
- 1 February 2023
- journal article
- review article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 29 (4-5) , 585-594
Abstract
Background: Data are sparse regarding the safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with multiple sclerosis (MS). Objective: To estimate (1) the pooled proportion of MS patients experiencing relapse among vaccine recipients; (2) the rate of transient neurological worsening, adverse events, and serious adverse events; (3) the previous outcomes of interest for different SARS-CoV-2 vaccine types. Methods: Systematic review and meta-analysis of pharmacovigilance registries and observational studies. Results: Nineteen observational studies comprising 14,755 MS patients who received 23,088 doses of COVID-19 vaccines were included. Mean age was 43.3 years (95% confidence interval (CI): 40–46.6); relapsing-remitting, secondary-progressive, primary-progressive MS and clinically isolated syndrome were diagnosed in 82.6% (95% CI: 73.9–89.8), 12.6% (95% CI: 6.3–20.8), 6.7% (95% CI: 4.2–9.9), and 2.9% (95% CI: 1–5.9) of cases, respectively. The pooled proportion of MS patients experiencing relapse at a mean time interval of 20 days (95% CI: 12–28.2) from vaccination was 1.9% (95% CI: 1.3%–2.6%; I 2 = 78%), with the relapse risk being independent of the type of administered SARS-CoV-2-vaccine ( p for subgroup differences = 0.7 for messenger RNA (mRNA), inactivated virus, and adenovector-based vaccines). After vaccination, transient neurological worsening was observed in 4.8% (95% CI: 2.3%–8.1%) of patients. Adverse events and serious adverse events were reported in 52.8% (95% CI: 46.7%–58.8%) and 0.1% (95% CI: 0%–0.2%) of vaccinations, respectively. Conclusion: COVID-19 vaccination does not appear to increase the risk of relapse and serious adverse events in MS. Weighted against the risks of SARS-CoV-2-related complications and MS exacerbations, these safety data provide compelling pro-vaccination arguments for MS patients.Keywords
This publication has 34 references indexed in Scilit:
- Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosisMultiple Sclerosis and Related Disorders, 2021
- Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19Neurology and Therapy, 2021
- COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021Multiple Sclerosis Journal, 2021
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventionsBMJ, 2016
- Closing the Gap between Methodologists and End-Users:Ras a Computational Back-EndJournal of Statistical Software, 2012
- Immunizations and risk of multiple sclerosis: systematic review and meta-analysisJournal of Neurology, 2011
- Assessing changes in relapse rates in multiple sclerosisMultiple Sclerosis Journal, 2010
- Conducting Meta-Analyses inRwith themetaforPackageJournal of Statistical Software, 2010
- Use of Bacille Calmette–Guèrin (BCG) in multiple sclerosisNeurology, 1999